Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
An Epstein-Barr virus negative disorder with a chronic clinical course affecting predominantly adults and characterized by the proliferation of large granular lymphocytes with natural killer cell immunophenotype. The T-cell receptor genes are not rearranged.
Biomarker and diagnostic research for chronic lymphoproliferative disorder of NK-cells has been reported in the published literature.
5 clinical trials registered, 5 recruiting. Interventions under study include drug therapy and other interventions. Pipeline includes 3 PHASE2. Research is primarily sponsored by academic and government institutions.
NCT ID | Title | Phase | Sponsor | Status |
|---|---|---|---|---|
[NCT06530550](https://clinicaltrials.gov/study/NCT06530550) |
Data assembled from 4 of 12 sources · Last updated Oct 4, 2026, 12:59 AM UTC
European rare disease database
Genetic and Rare Diseases Info Center
Common questions about chronic lymphoproliferative disorder of NK-cells
PI3K Inhibitors for the Treatment of Relapsed/Refractory Indolent T/NK-cell Lymphomas
PHASE2 |
Institute of Hematology & Blood Diseases Hospital, China |
RECRUITING |
[NCT07019766](https://clinicaltrials.gov/study/NCT07019766) | National Longitudinal Cohort of Hematological Diseases-Large Granular Lymphocytic Leukemia | — | Institute of Hematology & Blood Diseases Hospital, China | RECRUITING |
[NCT06530576](https://clinicaltrials.gov/study/NCT06530576) | Thalidomide for the Symptomatic Large Granular Lymphocytic Leukemia | PHASE2 | Institute of Hematology & Blood Diseases Hospital, China | RECRUITING |
[NCT06716658](https://clinicaltrials.gov/study/NCT06716658) | JAK1 Inhibitor Golidocitnib for the Treatment of Relapsed/Refractory Indolent T/NK-cell Lymphomas | PHASE2 | Institute of Hematology & Blood Diseases Hospital, China | RECRUITING |
[NCT02863692](https://clinicaltrials.gov/study/NCT02863692) | Registry of the German CLL Study Group | — | German CLL Study Group | RECRUITING |
8 publications have been identified in PubMed for chronic lymphoproliferative disorder of NK-cells. Research spans Case Report / Case Series (63%), Epidemiology / Natural History (25%), and Diagnostic / Biomarker (13%).
Liu B (2025). [PMID: 40699309](https://pubmed.ncbi.nlm.nih.gov/40699309/). *Ann Hematol*. [Case Report / Case Series]
Zhang HH (2025). [PMID: 41502251](https://pubmed.ncbi.nlm.nih.gov/41502251/). *Zhongguo Shi Yan Xue Ye Xue Za Zhi*. [Epidemiology / Natural History]
Wang W (2025). [PMID: 40646680](https://pubmed.ncbi.nlm.nih.gov/40646680/). *American journal of clinical pathology*. [Case Report / Case Series]
Shi M (2024). [PMID: 38823032](https://pubmed.ncbi.nlm.nih.gov/38823032/). *Am J Clin Pathol*. [Case Report / Case Series]
Morán-Plata FJ (2024). [PMID: 39040115](https://pubmed.ncbi.nlm.nih.gov/39040115/). *Front Immunol*. [Diagnostic / Biomarker]
Liu DL (2024). [PMID: 38319083](https://pubmed.ncbi.nlm.nih.gov/38319083/). *Hematology*. [Epidemiology / Natural History]
Shang L (2024). [PMID: 39661993](https://pubmed.ncbi.nlm.nih.gov/39661993/). *Clin Lab*. [Case Report / Case Series]
Yamada K (2024). [PMID: 39342133](https://pubmed.ncbi.nlm.nih.gov/39342133/). *BMC Neurol*. [Case Report / Case Series]